Journal of Clinical Oncology
Articles in this Issue
Barriers to germline genetic testing in advanced prostate cancer: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC).
e17073 Background: The NCCN began recommending germline genetic testing for individuals with high-risk or advanced prostate cancer (PCa) in 2017. In 2019,...
Genomic and circulating tumor DNA landscape in young-onset non-small cell lung cancer.
8528 Background: To explore the underlying biology in young patients (pts) with non-small cell lung cancer (NSCLC), we analyzed the genomic diversity of s...
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.
8507 Background: Sac-TMT (MK-2870/SKB264), a novel TROP2 ADC developed to conjugate a belotecan-derivative topoisomerase I...
Disparities in cancer screening and preventive care access among LGBTQ+ populations: A cross-sectional analysis.
10515 Background: The incidence and outcomes of certain health conditions, particularly cancers, can vary significantly across different sexual orientatio...
Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia (CLL).
e23264 Background: Next-generation BTKi monotherapy is a preferred first-line (1L) treatment (tx) option, as categorized by the NCCN guidelines, for patie...
Intervention adherence, engagement and tool utilization in the breast cancer weight loss (BWEL) trial by race and ethnicity (Alliance A011401).
1586 Background: Black and Hispanic breast cancer (BC) survivors have a higher prevalence of obesity and experience less success with weight loss interven...
Efficacy and safety of drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in unresectable gastric cancer with liver metastasis.
e16006 Background: Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer-related mortality worldwide. The liver is the pri...
Global burden of non-Burkitt non-Hodgkin’s lymphoma (NHL), 1990-2021.
e19052 Background: Non Burkitt Non-Hodgkin’s Lymphoma (NB-NHL) are rare hematological malignancies associated with a poorer prognosis and reduced survival...
Post-mastectomy surveillance: A patient-reported survey of 110 women with Li-Fraumeni syndrome.
10614 Background: Li-Fraumeni syndrome (LFS) is a highly penetrant autosomal dominant hereditary disorder associated with young onset breast cancer (BC)....
Results of BH011 after intravesical administration in patients with CIS and/or papillary non-muscle invasive bladder cancer (NMIBC) after BCG failure: Interim results from a phase I/II clinical trial.
4607 Background: Treatment options are limited for patients (pts) with high risk NMIBC (HR NMIBC) after BCG failure. BH011 is a novel docetaxel formulatio...
Real world evidence on treatment efficacy and safety of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
e18570 Background: Chronic myeloid leukemia (CML) treatment was revolutionaized with the introduction of tyrosine kinase inhibitors (TKIs) targeting BCR-A...
Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial.
2597 Background: Definitive concurrent chemoradiotherapy (dCCRT) is considered the standard treatment for esophageal squamous cell carcinoma (ESCC). The P...
Industry promotion of oncology drugs with accelerated approval that failed confirmatory trials.
11029 Background: Oncology drugs are commonly granted accelerated approval by FDA based on pivotal trials using surrogate markers as primary endpoints, wh...
Likelihood of colorectal cancer screening by poor health status: A cross-sectional analysis of the Behavioral Risk Factor Surveillance System 2022.
e15677 Background: Professional societies recommend against colorectal cancer (CRC) screening for adults over the age of 75, particularly those with a lif...
Prevalence of PD-L1 expression and <i>RAS</i> mutations and association with overall survival in metastatic colorectal cancer patients.
e15572 Background: Higher PD-L1 expression has been shown to be predictive of response to immune checkpoint inhibitors in some tumor types. However, the i...
Missing data and missed opportunities: Inability to perform secondary analysis of prospective randomized control trials due to missing general anesthesia data.
e23012 Background: Medications given to facilitate general anesthesia are known to impact recovery and may impact cancer outcomes after surgery. Most gene...
Androgen deprivation therapy and quality of life: A concept map analysis.
12067 Background: Androgen deprivation therapy (ADT) is the backbone of systemic treatments for prostate cancer (PC), but is associated with side effects...
Phase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC).
6023 Background: Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) but its clinical activity is limited by resistan...
Real world outcomes of EGFR-mutated non small cell lung cancer treated with surgery EXERPOS 02 GFPC study.
e20002 Background: There are few epidemiological and clinical data’s on No Small Cell Lung Cancer (NSCLC) Caucasians patients (pts) harboring EGFR mutatio...
Disparate recovery of cancer screenings by demographic in traditional Medicare post-pandemic.
11090 Background: Cancer screenings are a pillar of public health and early diagnosis of cancer (doi.org/10.1016/j.soncn.2017.02.002) The COVID 19 pandemi...
Enhancing clinical trial site efficiency and unlocking patient access to clinical trials using technology-enabled pre-screening.
e23122 Background: Despite significant advancements in cancer therapies, only 7% of adult cancer patients participate in clinical trials, according to the...
How do health concerns present in cancer survivors who require interpreters? Database analysis of a structured survivorship clinic for early-stage cancer.
1632 Background: Cancer survivors (CS) of Culturally and Linguistically Diverse (CALD) backgrounds face disparities in care. We aimed to compare demograph...
A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors.
TPS2670 Background: MDX2001 is a multispecific antibody recognizing CD3 and CD28 on T cells, and c-MET and TROP2 on tumors. Anti-CD3 provides the primary...
MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours.
e12613 Background: HER2+ accounts for 20–25 % of all BC, is aggressive and clinically challenging. Though treatment outcomes have improved with anti-HER2...
Pancreatic adenosquamous carcinoma (PASC): A comparative genomic landscape study.
4153 Background: PASC accounts for 1-4% of primary exocrine pancreatic malignancies and is associated with more aggressive disease biology and worse clini...